Yescarta has partnered with CAR- to improve the safety and effectiveness of first -generation CAR-T therapies. Xyphos has engineered the CD19 receptor inactive until a bispecific is administered, enabling the NKG2D receptor to bind to a tumour antigen. Xyphos ' method could also be used when mutating cancer cells render Novartis 's Novartis and Novartis ' Kymriah therapies ineffective in targeting the CD19 antigen.
Xyphos Biosciences has partnered with The Parker Institute for Cancer Immunotherapy to improve the safety and effectiveness of first-generation CAR-T therapies. Xyphos has engineered the NKG2D receptor inactive until a bispecific is administered, enabling the NKG2D receptor to bind to a tumour antigen. Xyphos' method could also be used when mutating cancer cells render Gilead's Yescarta and Novartis' Kymriah therapies ineffective in targeting the CD19 antigen.